PCVX
$55.48
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Intraday
Recent News
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)?
Vaxcyte, Inc. reported a full-year 2025 net loss of US$766.63 million, with basic loss per share from continuing operations of US$5.63, and simultaneously moved to strengthen its balance sheet through a US$408.10 million follow-on equity raise and an additional US$500 million at-the-market program. Alongside these financing steps, Vaxcyte filed a US$473.86 million shelf registration tied to employee stock plans and advanced its VAX-31 pneumococcal vaccine program into multiple late-stage...
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.
For growth-focused biotech investors, Vaxcyte is no longer just a science story.
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists
Vaxcyte (NasdaqGS:PCVX) reported unprecedented Phase 2 results in adults for its 31-valent pneumococcal vaccine candidate, VAX-31. The company is moving rapidly into multiple Phase 3 trials following the positive Phase 2 data. A large-scale manufacturing facility has been completed to support potential future commercial supply. Vaxcyte has appointed a new Chief Commercial Officer as it prepares for possible global commercialization. For investors watching Vaxcyte at a share price of $61.74,...
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds
Vaxcyte (PCVX) has been drawing attention after recent share price moves, with the stock closing at US$61.74 and showing mixed total returns over the past year and multi year periods. See our latest analysis for Vaxcyte. The recent 1 month share price return of 15.25% and 90 day return of 35.63% suggest momentum has been building, even though the 1 year total shareholder return of a 15.45% decline contrasts with the much stronger 3 and 5 year total shareholder returns of 45.13% and...
Vaxcyte, Inc. Q4 2025 Earnings Call Summary
Moby summary of Vaxcyte, Inc.'s Q4 2025 earnings call